Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.6283
-0.0108 (-1.69%)
At close: Aug 29, 2025, 4:00 PM
0.6247
-0.0036 (-0.57%)
After-hours: Aug 29, 2025, 6:39 PM EDT
Silo Pharma Employees
Silo Pharma had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,034
Profits / Employee
-$1,631,721
Market Cap
5.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 1 | 50.00% |
| Dec 31, 2021 | 2 | 1 | 100.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SILO News
- 11 days ago - Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - GlobeNewsWire
- 13 days ago - Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway - GlobeNewsWire
- 27 days ago - Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform - GlobeNewsWire
- 6 weeks ago - Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 - GlobeNewsWire
- 2 months ago - Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 - GlobeNewsWire
- 2 months ago - Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market - GlobeNewsWire
- 2 months ago - Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. - PRNewsWire
- 2 months ago - Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - GlobeNewsWire